Abcellera Biologics Inc. · NASDAQ:ABCL
Abcellera Biologics — Q1 2024 Earnings Presentation
14 slides from Abcellera Biologics's earnings presentation, May 7, 2024
Slide 1: Q1 2024 Business Update
Q1 2024 BUSINESS UPDATE MAY 7, 2024 COPYRIGHT © ABCELLERA
Slide 2: Disclaimer
DISCLAIMER Q1 2024 BUSINESS UPDATE This presentation contains forward-looking statements, including statements These statements involve risks, uncertainties and other factors that may made pursuant to the safe harbor provisions of the Private Securities cause actual results, levels of activity, perf
Slide 3: 2024 Priorities
2024 PRIORITIES As we move programs toward the clinic, we are prioritizing: Q1 2024 BUSINESS UPDATE 1 2 3 Internal Engine & Strategic Programs & Capabilities Partnerships Pipeline COPYRIGHT © ABCELLERA 3
Slide 4: Our Engine: Platform Development
OUR ENGINE. PLATFORM DEVELOPMENT New data demonstrates highly differentiated T-cell engager platform. Q1 2024 BUSINESS UPDATE COPYRIGHT © ABCELLERA Presented at AACR 2024 4
Slide 5: Widening the therapeutic window across solid tumor indications
OUR ENGINE. PLATFORM DEVELOPMENT Widening the Potent molecules with functional profiles that rival clinical benchmarks therapeutic window across Q1 2024 BUSINESS UPDATE solid tumor indications. We describe the generation of T-cell engagers for three solid tumor targets, PSMA, B7-H4, and 5T4, with fu
Slide 6: T-cell engager platform as source of internal programs and partnerships
OUR ENGINE. PLATFORM DEVELOPMENT We are using our T-cell engager platform as a source of internal programs and a basis for strategic partnerships. Q1 2024 BUSINESS UPDATE Our focus is to test in vivo and to advance a subset of programs. Our TCE platform is nearly complete. In addition to having high
Slide 7: Our Partners
OUR PARTNERS We advanced strategic partnerships with established biopharmas and top-tier investment groups. Q1 2024 BUSINESS UPDATE ESTABLISHED 1 Program NEUROLOGY BIOPHARMA COMPANY CREATION Multiple Programs IMMUNOLOGY with Investment Groups COPYRIGHT © ABCELLERA 7
Slide 8: Q1 2024 Financials Update
Q1 2024 COPYRIGHT © ABCELLERA FINANCIALS UPDATE
Slide 9: Continued progress on key business metrics and a strong cash position
~$1B In available liquidity to execute on our strategy Continued Q1 2024 BUSINESS UPDATE $725M in total cash, cash equivalents, & progress on key marketable securities business metrics 90 cumulative partner- initiated program starts with downstreams and a strong cash position. 13 molecules in the cl
Slide 10: Financials: Continuing portfolio growth
FINANCIALS Continuing portfolio growth. Cumulative # of Cumulative # of PARTNER-INITIATED PROGRAM STARTS MOLECULES IN THE CLINIC WITH DOWNSTREAMS Q1 2024 BUSINESS UPDATE 90 13 90 13 12 80 11 70 10 60 9 8 50 7 40 6 5 30 4 20 3 2 10 1 0 0 COPYRIGHT © ABCELLERA 2015 16 17 18 19 20 21 22 23 24 2015 16 1
Slide 11: Financials: Revenue and operating expenses
FINANCIALS Operating expenses reflect ongoing investments, predominantly in R&D; partly offset by $10M in revenue. Revenue USD Operating Expenses USD MILESTONES RESEARCH & SALES & GENERAL & LICENSING DEVELOPMENT MARKETING ADMIN Q1 2024 BUSINESS UPDATE RESEARCH FEES -$13.4M $52.6M $39.3M +$2.2M $12.2
Slide 12: Financials: Net loss and earnings per share
FINANCIALS Net loss of $41M; equivalent to ($0.14) per share (basic & diluted). Earnings USD NET EARNINGS EARNINGS PER SHARE: Q1 2024 BUSINESS UPDATE BASIC AND DILUTED -$40.1M -$40.6M -$0.14 -$0.14 COPYRIGHT © ABCELLERA Q1 2023 Q1 2024 Q1 2023 Q1 2024 12
Slide 13: Financials: Cash flows and total cash position
FINANCIALS Approximately $725M in total cash, equivalents, and marketable securities. Cash Flows USD $788M $725M Q1 2024 BUSINESS UPDATE $627M Marketable Securities $574M Marketable Securities $30M $57M Marketable $3M $133M Cash & Securities (net) ($27M) Other ($1M) $124M Equivalents ($42M) Cash & C
Slide 14: Thank You
COPYRIGHT © ABCELLERA 14 Q1 2024 BUSINESS UPDATE YOU THANK